Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
US10696652B2 · kind B2 · utility
0Cited by
1References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 25, 2018 |
| Grant date | Jun 30, 2020 |
| Priority date | — |
| Expiry date | Apr 25, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating a mammal suffering from a cancer responsive to inhibition of protein kinase activity, by administering to the mammal an amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, effective to inhibit protein kinase activity, wherein the compound of formula (I) is:
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.